AXT's InP Surge Validates Demand but Execution Risks Remain

What happened

AXT's recent disclosures show accelerating indium phosphide demand, with record substrate sales and a backlog now exceeding $100 million, driven by AI-optics and data-center orders for 6-inch wafers. The company is expanding capacity, with targets to double InP output by end-2026, and has secured multi-year agreements including a binding 3-year Coherent deal with prepayment. However, the master report flagged that all wafer production is in China, and export permits remain the key gating factor, with North America revenue still negligible and inventory already high at $90.2 million as of Q1. The recent positive data mitigates some demand uncertainty but does not resolve the conversion of backlog into shipped revenue, especially given Coherent's own internal capacity expansion. At the current price, the stock already discounts a substantial growth scenario, and discipline requires waiting for consistent shipment growth before upgrading from WAIT.

Implication

The $100M+ backlog validates the AI-optics demand thesis and reduces the risk that the Coherent deal was a one-off. However, the backlog includes orders that may still require export permits, so it does not guarantee near-term revenue recognition. Inventory at $90.2M and rising working capital suggest that production is outpacing shipments, and if permits stall, margin compression could follow. Coherent's internal capacity expansion remains a medium-term risk to AXT's external demand, especially if scarcity eases. Investors should watch for Q3 revenue and inventory trends, and only consider adding if substrate revenue exceeds $22M with inventory below $95M, per the report's upgrade conditions.

Thesis delta

The new disclosures of record InP sales and a $100M+ backlog strengthen the bull case's demand assumption, but they do not alter the core thesis that shippable volume, not order activity, drives returns. The risk profile shifts modestly from 'demand unproven' to 'execution and permit risk', leaving the WAIT rating intact but leaning constructive.